arrow
N

Nicholas J. Vogelzang

Cleveland Clinic Foundation
H指数:115
被引数:6.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel
2024-02-016
OA
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
2023-03-227
OAAI
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib
2023-03-0124
OA
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study
2021-12-1514
OA
Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial

阿特珠单抗与化疗在铂类治疗的局部晚期或转移性尿路上皮癌患者中的比较: IMvigor211 3期临床试验的长期总生存率和安全性更新

2021-07-0158
PREAI
Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial

ECOG3805 CHAARTED试验中转移性激素敏感性前列腺癌的癌症进展模式

2020-12-0120
OAAI
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

转移性去势抵抗性前列腺癌中非BRCA DNA损伤修复基因改变和对PARP抑制剂Rucaparib的反应: 来自II期TRITON2研究的分析

2020-06-01296
OAAI
Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC)-final PROCEED analysis
2020-06-010
PRE
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
LANCET
IF88.5
2020-05-01584
PREAI